24/7 Market News Snapshot 09 October, 2025 – Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX)

October 9, 2025

DENVER, Colo., 09 October, 2025 (www.247marketnews.com) – (NASDAQ:AMIX) are discussed in this article.
Autonomix Medical, Inc. (NASDAQ:AMIX) is witnessing a significant surge in its stock performance, with its pre-market price climbing to $1.304, a substantial increase of approximately 6.89% from the previous close of $1.220. This bullish trend is underscored by an impressive trading volume of 1.61 million shares, reflecting heightened investor interest and potential momentum in the stock. Key technical indicators, including moving averages, are poised to confirm this positive sentiment, while traders should monitor resistance levels around $1.30 and support near $1.25 to assess the sustainability of this uptrend.

In a major development, Autonomix Medical has announced the issuance of U.S. Patent No. 12,369,852 by the United States Patent and Trademark Office, titled “Controlled and Precise Treatment of Cardiac Tissues.” This crucial patent strengthens the company’s intellectual property portfolio and signals its commitment to advancing innovative therapeutic solutions through precision nerve-targeted treatments in cardiology.

The patented technology encompasses advanced systems, devices, and methods that can sense autonomic and cardiac signals, facilitating targeted treatment of cardiac tissues through feedback-driven neuromodulation, denervation, and ablation techniques. This innovation positions Autonomix strategically in a rapidly expanding multi-billion-dollar market focused on alleviating high-burden cardiovascular and renal diseases.

Brad Hauser, CEO of Autonomix, expressed optimism regarding the new patent, highlighting its potential to revolutionize treatment methodologies for conditions such as heart failure, arrhythmias, and resistant hypertension while minimizing adverse effects linked with conventional therapies. The patent emphasizes the applications of this technology in critical areas including arrhythmias, ischemia, and hypertension, showcasing its versatility in enhancing patient care through localized, feedback-guided interventions.

As Autonomix tracks its progress at the forefront of medical innovation, it remains committed to leveraging its proprietary technology to redefine therapeutic approaches in healthcare.

Related news for (AMIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.